Global Hip Osteoarthritis Therapeutics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Hip Osteoarthritis Therapeutics Market Size

• The global hip osteoarthritis therapeutics market size was valued at USD 1.38 billion in 2024 and is expected to reach USD 2.38 billion by 2032, at a CAGR of 7.10% during the forecast period
• The market growth is largely fueled by the increasing prevalence of hip osteoarthritis worldwide and the rising aging population, which is more susceptible to joint degeneration and mobility issues. This growing patient pool is driving demand for effective therapeutic interventions, including pharmacological treatments and non-pharmacological management strategies
• Furthermore, advancements in drug development, increased healthcare spending, and improved access to diagnostic tools are contributing to the wider adoption of Hip Osteoarthritis Therapeutics. These converging factors are accelerating the uptake of targeted therapies, regenerative medicine, and combination treatment options, thereby significantly boosting the industry's growth

Hip Osteoarthritis Therapeutics Market Analysis

• Hip osteoarthritis therapeutics, encompassing pharmacological and non-pharmacological treatments, are increasingly vital in managing pain, improving joint function, and enhancing quality of life for aging populations globally, particularly in both clinical and home care settings due to their non-invasive nature and ease of administration
• The escalating demand for hip osteoarthritis therapies is primarily fueled by the growing aging population, increasing obesity rates, and rising awareness about early intervention and personalized treatment options
• North America dominated the hip osteoarthritis therapeutics market with the largest revenue share of 38.7% in 2024, characterized by early adoption of advanced biologics, strong reimbursement frameworks, and a high prevalence of osteoarthritis, with the U.S. experiencing substantial growth in diagnosis and treatment rates, particularly with the support of public and private healthcare initiatives
• Asia-Pacific is expected to be the fastest growing region in the hip osteoarthritis therapeutics market during the forecast period, due to rapid urbanization, increasing healthcare investments, rising elderly population, and growing access to quality healthcare in countries such as China, Japan, and India
• The prescription drugs segment dominated the hip osteoarthritis therapeutics market with a revenue share of 65.4% in 2024, driven by the increasing reliance on physician-recommended therapies for pain management and inflammation control

Report Scope and Hip Osteoarthritis Therapeutics Market Segmentation     

Hip Osteoarthritis Therapeutics Market Trends

“Rising Patient-Centric Innovation and Digital Health Integration”

• A significant and accelerating trend in the global hip osteoarthritis therapeutics market is the growing incorporation of digital health tools, remote monitoring, and personalized medicine to enhance treatment accessibility and patient compliance
  • For instance, smart wearable technologies and mobile health applications are being developed to help patients track pain levels, medication schedules, and physical activity. These tools enable real-time feedback for both patients and physicians, allowing for better treatment adjustments and improved outcomes
• Artificial intelligence is increasingly being used in clinical research and diagnostics to predict disease progression, suggest personalized treatment plans, and identify ideal candidates for specific drug therapies. This digital shift is reshaping the way chronic musculoskeletal conditions are managed
• Remote telehealth consultations are now widely used in managing hip osteoarthritis, especially among aging populations with mobility limitations. This improves follow-up care and supports long-term disease monitoring from the comfort of a patient’s home
• Pharmaceutical companies and health tech firms are increasingly collaborating to integrate therapeutic regimens with patient apps, digital reminders, and adherence monitoring systems, reducing treatment dropouts and improving quality of life
• The demand for patient-centric, connected, and data-driven osteoarthritis care is driving innovation in the Hip Osteoarthritis Therapeutics market, making personalized and tech-enabled treatments a key competitive edge for market players

Hip Osteoarthritis Therapeutics Market Dynamics

Driver

“Growing Need Due to Aging Population, Sedentary Lifestyles, and Early Disease Management”

• The increasing prevalence of hip osteoarthritis, especially among aging populations and individuals with sedentary lifestyles, is a major driver fueling demand for advanced therapeutics. The global rise in obesity and longer life expectancy are further contributing to higher incidences of joint degeneration 
  • For instance, in April 2024, Pfizer Inc. announced a new clinical trial phase for a novel intra-articular injection aimed at early-stage hip osteoarthritis management, signaling continued innovation and investment in the therapeutic space. Such initiatives by key players are expected to drive the Hip Osteoarthritis Therapeutics industry growth in the forecast period
• As patients seek less invasive alternatives to hip replacement surgery, demand is growing for pharmacologic options such as NSAIDs, corticosteroids, and hyaluronic acid injections. These offer effective pain relief, inflammation control, and improved joint function with reduced recovery times
• Furthermore, growing public awareness of joint health, coupled with enhanced access to orthopedic care, is making early diagnosis and treatment more widespread. This is leading to greater uptake of therapeutics that can delay or prevent the need for surgical interventions
• Comprehensive disease management through multimodal therapy—including medication, physical therapy, and lifestyle changes—is becoming the standard of care. This trend is expected to increase the use of combination therapeutics and customized treatment regimens, further driving market expansion

Restraint/Challenge

“High Treatment Costs and Limited Access in Developing Regions”

• The high cost of advanced therapies, including biologics and intra-articular injections, remains a barrier to adoption, particularly in low- and middle-income countries. The cost of prolonged treatment regimens, frequent clinical visits, and supportive diagnostic imaging adds to the overall financial burden
  • For instance, hyaluronic acid injections and biologics like platelet-rich plasma (PRP) are not always covered by public health insurance systems, limiting their reach to only higher-income patient populations in many countries
• Limited access to orthopedic specialists and diagnostic facilities in rural and underserved areas also hinders timely diagnosis and treatment, leading to disease progression and the eventual need for costly surgical interventions
• In addition, the regulatory approval process for new drugs and therapies is time-consuming and complex, delaying the availability of innovative treatment options in several markets
• Overcoming these challenges will require healthcare policy improvements, greater insurance coverage, expanded telemedicine use, and pharmaceutical strategies focused on cost-effective treatment development for global scalability

Hip Osteoarthritis Therapeutics Market Scope

The market is segmented on the basis of drug type, route of administration, dosage form, drug class, and distribution channel.

• By Drug Type

On the basis of drug type, the hip osteoarthritis therapeutics market is segmented into prescription drugs and over-the-counter drugs. The prescription drugs segment dominated the largest market revenue share of 65.4% in 2024, driven by the increasing reliance on physician-recommended therapies for pain management and inflammation control. Prescription-based viscosupplements and corticosteroid injections are widely adopted due to their targeted efficacy and prolonged relief from osteoarthritis symptoms.

The over-the-counter (OTC) segment is expected to witness the fastest growth rate of 20.2% from 2025 to 2032, propelled by growing patient preference for self-medication, easier accessibility, and the expanding availability of OTC NSAIDs and analgesics in both retail and online channels.

• By Route of Administration

On the basis of route of administration, the hip osteoarthritis therapeutics market is segmented into oral, parenteral, and topical. The oral segment held the largest market revenue share of 51.6% in 2024, due to ease of use, wide availability, and patient compliance with NSAIDs and analgesics taken orally.

The parenteral segment is expected to witness the fastest CAGR of 21.1% during the forecast period, driven by the effectiveness of injectable viscosupplements and corticosteroids for advanced-stage osteoarthritis patients who require immediate or localized relief.

• By Dosage Form

On the basis of dosage form, the hip osteoarthritis therapeutics market is segmented into tablets, injections, and others. The tablets segment accounted for the largest market share of 48.7% in 2024, supported by strong demand for oral NSAIDs and pain relievers that provide systemic pain relief.

The injections segment is anticipated to register the fastest CAGR of 23.5% from 2025 to 2032, attributed to the growing popularity of intra-articular therapies like hyaluronic acid and corticosteroids, which provide extended relief for hip joint discomfort.

• By Drug Class

On the basis of drug class, the hip osteoarthritis therapeutics market is segmented into viscosupplementation agents, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, corticosteroids, and others. The NSAIDs segment dominated with a revenue share of 39.9% in 2024, owing to their widespread use as first-line therapy for managing osteoarthritic pain and inflammation.

Viscosupplementation agents are expected to grow at the highest CAGR of 22.8% during the forecast period, supported by rising clinical adoption and advancements in long-acting hyaluronic acid formulations specifically designed for hip joints.

• By Distribution Channel

On the basis of distribution channel, the hip osteoarthritis therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment captured the largest market revenue share of 45.3% in 2024, owing to the dominance of prescription-based therapies administered or dispensed through hospitals and orthopedic clinics.

The online pharmacy segment is projected to experience the fastest CAGR of 25.4% from 2025 to 2032, driven by increasing digitalization in healthcare, rising patient preference for home delivery, and the availability of a broad range of OTC osteoarthritis medications online.

Hip Osteoarthritis Therapeutics Market Regional Analysis

• North America dominated the hip osteoarthritis therapeutics market with the largest revenue share of 38.7% in 2024, driven by rising awareness of early intervention treatments, increased prevalence of osteoarthritis among the aging population, and widespread availability of advanced therapeutic options including NSAIDs, corticosteroids, and biologics
• Favorable reimbursement policies, a strong presence of key pharmaceutical players, and robust healthcare infrastructure further support the market’s growth across the region
• The market is being propelled by growing patient demand for non-invasive treatments to delay or avoid hip replacement surgery, as well as increased clinical research on emerging intra-articular therapies

U.S. Hip Osteoarthritis Therapeutics Market Insight

The U.S. hip osteoarthritis therapeutics market accounted for 75% of North America’s total revenue in 2024, owing to high treatment awareness, strong insurance coverage, and rapid uptake of novel therapies such as platelet-rich plasma (PRP) and stem cell-based injections. An aging demographic, sedentary lifestyles, and obesity trends continue to drive demand. Moreover, the country’s focus on research and clinical trials, supported by both government funding and private initiatives, enhances access to advanced therapeutics and accelerates market penetration.

Europe Hip Osteoarthritis Therapeutics Market Insight

The Europe hip osteoarthritis therapeutics market is projected to register a robust CAGR of 7.5% from 2025 to 2032, driven by an increasing elderly population and the expansion of public healthcare programs covering osteoarthritis treatment. Countries such as Germany, France, and the U.K. are investing in awareness campaigns and early-stage disease screening. Growing adoption of minimally invasive therapies and improved access to specialist consultations are driving regional growth.

U.K. Hip Osteoarthritis Therapeutics Market Insight

The U.K. hip osteoarthritis therapeutics market is expected to grow at a CAGR of 7.9% during the forecast period, backed by NHS-backed initiatives focused on managing chronic joint pain without resorting to surgery. Rising obesity rates and joint damage from high-impact sports are further pushing demand. The U.K. is also seeing a growing interest in natural supplements and combination therapies for osteoarthritis pain relief.

Germany Hip Osteoarthritis Therapeutics Market Insight

The Germany hip osteoarthritis therapeutics market is anticipated to grow at a CAGR of 7.6%, supported by the country’s aging population and a healthcare system that emphasizes early diagnosis and therapeutic intervention. Germany’s demand is also being fueled by the increasing use of digital health monitoring to personalize treatment plans and track therapy effectiveness.

Asia-Pacific Hip Osteoarthritis Therapeutics Market Insight

The Asia-Pacific hip osteoarthritis therapeutics market is projected to grow at the fastest CAGR of 9.2% from 2025 to 2032, driven by increasing disease burden, improved healthcare accessibility, and rising disposable incomes in countries like China, India, and Japan. Public health initiatives aimed at improving mobility in aging populations and rising urbanization, which correlates with a more sedentary lifestyle, are major contributing factors.

Japan Hip Osteoarthritis Therapeutics Market Insight

The Japan hip osteoarthritis therapeutics market is experiencing significant traction, with demand for non-surgical pain relief solutions driven by one of the world's oldest populations. Government-led healthy aging initiatives, paired with strong interest in regenerative medicine and conservative treatment options, support this market's development.

China Hip Osteoarthritis Therapeutics Market Insight

China hip osteoarthritis therapeutics market captured the largest share of the Asia-Pacific market in 2024, bolstered by urban lifestyle shifts, the prevalence of overweight individuals, and rapidly growing healthcare infrastructure. Government investments in elderly care and growing patient awareness of osteoarthritis therapies are fostering accelerated market growth. The expansion of local manufacturing and drug production is also making treatments more affordable and accessible.

Hip Osteoarthritis Therapeutics Market Share

The hip osteoarthritis therapeutics industry is primarily led by well-established companies, including:

• Bayer (Germany)
• Lilly (U.S.)
• GSK Plc (U.K.)
• Johnson & Johnson and its affiliates (U.S.)
• Merck & Co., Inc. (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Sanofi S.A. (France)
• Zimmer Biomet (U.S.)
• Anika Therapeutics Inc. (U.S.)
• Bioventus (U.S.)
• Flexion Therapeutics, Inc. (U.S.)
• OrthogenRx, Inc. (U.S.)
• Pacira Pharmaceuticals, Inc. (U.S.)

Latest Developments in Global Hip Osteoarthritis Therapeutics Market

• In April 2025, researchers published results from the largest genome-wide association study on osteoarthritis, analyzing nearly 2 million individuals—including 500,000 with OA. The study identified 962 genetic markers, 513 of which are novel, uncovering hundreds of potential new drug targets and opportunities for repurposed therapies in hip OA
• In March 2025, Lipogems announced the final patient enrollment in its ARISE II U.S. FDA IDE study, comparing MicroFat intra-articular injections against placebo for knee and hip osteoarthritis. The randomized trial involved 173 subjects across 16 U.S. sites; results on pain and function are expected in late 2025

SKU-70780